DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
Netherlands-based DSM has invested an undisclosed sum in Danish
purification technology company Upfront Chromatography to boost its
protein separation business.